자디앙듀오 (엠파글리플로진) 12.5 mg, Jardianduo (Empagliflozin) 12.5 mg

Dosing: Adult

Note: Hypovolemia, if present, should be corrected prior to initiating treatment.

​

Diabetes mellitus, type 2, treatment:

​

Note: May be used as an adjunctive agent or alternative monotherapy for patients who fail initial therapy with lifestyle intervention and metformin or cannot take metformin. Empagliflozin may be preferred as an additional antidiabetic agent or alternative first-line agent in patients with atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease (ADA 2020; Zelniker 2019; Zinman 2015).

​

Oral: Initial: 10 mg once daily; may increase to 25 mg once daily if needed to achieve glycemic goals.

​

Use in patients with diabetic nephropathy (off-label use): Although the manufacturer recommends against routine use in patients with eGFR <45 mL/minute/1.73 m2, in the setting of prevalent kidney disease, SGLT2 inhibitors have established renal and cardiovascular benefits when eGFR is >30 mL/minute/1.73 m2 (Perkovic 2020; Wanner 2016; Wanner 2018; Zelniker 2019). Because SGLT2 inhibitors have less glycemic benefit as eGFR declines, another agent may be needed to achieve glycemic goals (Wexler 2020).

​

REF. UpToDate 2020.05.19